All News

The supplemental biologics license application for amivantamab-vmjw (Rybrevant) is supported by data from the phase 3 PAPILLON trial, evaluating the efficacy and safety of the drug in combination with chemotherapy for those with non–small cell lung cancer.

The kinase inhibitor is already approved for patients who experienced recurrence following 1 or more lines of standard of care platinum-containing chemotherapy.

Investigators from Griffith University stated that technology has helped the development of vaccines that are safe to use and induce strong immune responses against Strep A.

Luspatercept-aamt (Reblozyl) approved to treat adults with very low- to intermediate-risk myelodysplastic syndrome who may require regular red blood cell transfusions.

Women with myalgic encephalomyelitis/chronic fatigue syndrome for more than 10 years are more likely to have increased severity in their symptoms as they age.

This technique may be applied to transdermal applications, such as shot-free vaccines.

The start date of the package-level electronic tracking system will shift from November 27, 2023 to November 27, 2024.

Advanced technology can automate many pharmacovigilance tasks to build workflow efficiencies, reduce manual intervention, and free up team members for more strategic activities.

Perhaps the most significant development in the pharmaceutical industry in decades, crops of biosimilars are being approved and are ready for distribution. What lies next, in terms of legislation and the impact on pharmacists, remains to be seen.

This social determinant of health could have the same level of negative impact on health as the experience of racism, poverty, or low education.

Pharmacists' expertise is invaluable to prescribers who are unfamiliar with opioid use disorder treatment protocols.

Investigators found that artificial intelligence chatbots did not consistently provide recommendations for cancer treatment that correspond with NCCN guidelines.

With the help of new and complex algorithms and self-learning models, we are currently privy to what we may look back on as the golden era of AI.

KET01 could successfully treat treatment-resistant depression while limiting adverse effects in the home environment, according to the study.

Although the patient demographics are similar for the 3 categories of hemolytic reactions with intravenous immunoglobulin, the reaction with delayed hemolytic transfusion reactions was highest compared to the other 2 hemolytic reactions.

The research was aided by the Decipher Genomics Resource for Intelligent Discovery, which helped derive the gene signatures used during the analysis.

The FDA is the first regulatory agency globally to approve natalizumab-sztn as a biosimilar for natalizumab.

The drug can now be tested for safety, tolerability, and efficacy in a phase 1 study.

There is lots of information about matters of women's health online, both true and untrue, but pharmacists remain a credible source for educating women about health matters.

Tailor pharmacy roles based on skill sets, although every technician must be capable of basic professional communication.

The digital cessation platform is the first FDA-cleared OTC device to help individuals quit smoking tobacco.

Tom Knight, founder and CEO of Invistics, now part of Wolters Kluwer, discusses the dangers of drug diversion and how this could negatively impact affect patients.

The recent discovery could aid further research on the cause of Huntington’s disease and other inherited conditions.

Investigators determined that there needs to be an evaluation of harm caused by pharmacy professionals who are in unique positions on social media, propagating misinformation about COVID-19, vaccines, treatment, masks, and other conspiracy theories.

Participants indicated that they would be more likely to accept PrEP-related information if it was recommended by a trusted person.

The drug is the first approved antiviral COVID-19 treatment that could be used across all stages of liver disease.

UB-311 has shown to be well-tolerated with a durable antibody response in a previous phase 1 trial, and new results from a phase 2a study support its continued development.

Cases address malaise and hyperglycemia.

The phase 3 study will advance the safety findings of survodutide reported in the phase 2 study to aid overweight and obesity.